"10.1371_journal.pone.0072949","plos one","2013-09-09T00:00:00Z","Jörg Tomeczkowski; Sean Stern; Alfred Müller; Christian von Heymann","Department of Health Economics, Janssen-Cilag GmbH, Neuss, Germany; United Biosource Corporation, Bethesda, Maryland, United States of America; Analytic Services GmbH, München, Germany; Department of Anesthesiology and Intensive Care Medicine, Charité-University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany","Conceived and designed the experiments: JT AM SS CvH. Performed the experiments: JT AM. Analyzed the data: JT AM SS CvH. Contributed reagents/materials/analysis tools: JT AM CvH. Wrote the paper: JT AM SS CvH.","JT is an employee of Janssen-Cilag GmbH (Johnson & Johnson). Janssen-Cilag holds the marketing authorization for ERYPO®/EPREX®/PROCRIT® (Epoetin alfa) used in this model. SS is an employee of United Biosource Corporation and received an honorarium for the model validation and for working on the manuscript. AM received an honorarium for the programming of the model. CvH has received honoraria for consultancy work and lectures from Janssen-Cilag GmbH (Johnson & Johnson), Vifor Pharma GmbH, Munich, and the German Red Cross, Hagen, Germany. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","09","Jörg Tomeczkowski","JT",4,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
